Cell And Gene Therapy Analytics

1. Successful Microbial Testing And Identification 5/27/2025

   In this presentation, one of our industry-leading customers discusses how they've successfully implemented the Applied Biosystems MicroSEQ Microbial Identification System in their laboratory testing.

2. Multi-Omics And Bioinformatics In Cell Culture Media Design 6/16/2025

   Learn about the impact of a multi-omics analysis, utilizing proteomics and metabolomics, in the development and optimization of media with the goal of improving titer, and making development and manufacturing more efficient.

3. Leveraging Rapid Sterility Testing To Advance Cell Therapy Production 6/23/2025

   Explore the crucial role of rapid sterility testing in cell therapy manufacturing. This presentation delves into the benefits of swift, accurate detection for product quality and patient safety.

4. Interview With Nico Chow And Sandi True, Field Applications Specialists 11/6/2025

   Hear Nico Chow and Sandi True, Field Applications Specialists, discuss working with customers to help them evaluate and implement Residual DNA Quantitation, Mycoplasma Detection, and Microbial Identification Assays.

5. Validation Of A qPCR Assay For Host Cell DNA Quantitation 6/9/2025

   Here, we share the development and validation of a new, highly sensitive and accurate integrated solution for detection and quantitation of host cell DNA to help meet regulatory requirements.

6. Microbial Identification Via DNA-Seq 6/9/2025

   Learn how DNA sequencing-based microbial identification supports regulatory compliance and enhances contamination control in critical environments.

7. An All-In-One Solution For Residual DNA Quantitation 5/22/2025

   Explore an all-in-one solution for residual DNA quantitation with a 3D lab tour with virtual demos, videos, and interactive instrument guides to experience the full workflow.

8. Manufacturing Hurdles With Viral Vectors 11/13/2023

   With a wide range of viral vector-based drugs already approved, viral vectors are expected to remain the primary delivery mechanism for the foreseeable future. However, as the demand for viral vectors increases, addressing the challenges related to their manufacture and scale-up is critical. In this segment, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO share what they consider to be the most difficult challenges in vector development and manufacturing currently.

9. Cell And Gene Therapy Innovations 5/19/2025

   This interview with a pharmaceutical analytics expert discusses key insights into advances in cell and gene therapy and the strategies used to support customers in improving their therapeutic development.

10. Analytical Approaches For Quantifying Residual Host Cell DNA 5/29/2025

    In this webinar, we’ll discuss the challenges, risks and considerations involved in developing and using in-house residual testing solutions, and the benefits of using commercial kits for residual DNA testing.